Aron Goldhirsch

Research interests

Publications

• Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

  JNCI Journal of the National Cancer Institute · 2019 · https://doi.org/10.1093/jnci/djz094

• Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30261-4

• 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(16)32616-2

• Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.62.3504

• Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.62.1797

• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv221

• Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1404037

• Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1412379

• Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.46.1574

• Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

  The Lancet Oncology · 2013 · https://doi.org/10.1016/s1470-2045(13)70035-4

• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt303

• CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

  JNCI Journal of the National Cancer Institute · 2012 · https://doi.org/10.1093/jnci/djs125

• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

  The Lancet · 2012 · 10.1016/s0140-6736(11)61847-3

• 1st International consensus guidelines for advanced breast cancer (ABC 1)

  The Breast · 2012 · https://doi.org/10.1016/j.breast.2012.03.003

• Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer

  Annals of Oncology · 2010 · https://doi.org/10.1093/annonc/mdq072

• Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2009.22.0962

• Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2008.17.0829

• Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer

  JNCI Journal of the National Cancer Institute · 2008 · https://doi.org/10.1093/jnci/djm289

• Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2007.14.9336

• 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

  The Lancet · 2007 · 10.1016/s0140-6736(07)60028-2

• Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2007.11.9453

• Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays

  JNCI Journal of the National Cancer Institute · 2006 · https://doi.org/10.1093/jnci/djj415

• Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

  Journal of Clinical Oncology · 2006 · 10.1200/jco.2005.02.6187

• Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

  New England Journal of Medicine · 2005 · 10.1056/nejmoa052306

• Breast cancer

  The Lancet · 2005 · https://doi.org/10.1016/s0140-6736(05)66546-4

• A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers

  JNCI Journal of the National Cancer Institute · 2003 · https://doi.org/10.1093/jnci/95.11.779

• Very young women (<35 years) with operable breast cancer: features of disease at presentation

  Annals of Oncology · 2002 · https://doi.org/10.1093/annonc/mdf039

• Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

  Annals of Oncology · 2002 · https://doi.org/10.1093/annonc/mdf013

Current projects

No projects listed.